Keith Kleeman ’97
Alumni Innovator-in-Residence
Mr. Kleeman is an entrepreneur, biotechnology executive, and commercialization strategist with more than 20 years of experience founding, financing, scaling, and exiting biotechnology and healthcare technology companies. His expertise lies in translating breakthrough scientific innovations into venture-backed companies and commercially viable products through strategic business development, fundraising, regulatory planning, and technology commercialization.
As Founder and CEO of multiple biotechnology companies, he has secured venture financing, recruited world-class scientific leadership, and guided emerging technologies from concept to commercialization. His experience spans synthetic biology, biomanufacturing, artificial intelligence, clinical research, regulatory science, and pharmaceutical development.
He is currently Founder and Acting CEO of Celvant, developing a synthetic biology manufacturing platform that strengthens domestic pharmaceutical manufacturing capabilities through next-generation biomanufacturing technologies. He also founded and is CEO for Optimvia, a synthetic biology company developing enzyme-based manufacturing of synthetic heparin, and recruited a world-class scientific and commercialization advisory team while leading successful Series A and B fundraising efforts.
Previously, he founded ClinGenuity, which developed the pharmaceutical industry's first artificial intelligence platform using natural language processing to automate regulatory document development. Following its merger with Medical Communication Consultants, the company was acquired by Certara, where he served as Vice President of Strategy and Clinical Innovation, leading integration and commercialization of advanced clinical technologies.
Earlier, he founded Medical Communication Consultants, building a leading medical writing organization that supported the development and regulatory approval of more than 15 marketed therapeutics. He began his career at Eli Lilly and Company, contributing to multiple successful New Drug Applications in oncology.